Ta. Jacobson et al., Impact of evidence-based "clinical judgment" on the number of American adults requiring lipid-lowering therapy based on updated NHANES III data, ARCH IN MED, 160(9), 2000, pp. 1361-1369
Citations number
36
Categorie Soggetti
General & Internal Medicine","Medical Research General Topics
Background: When the National Cholesterol Education Program Adult Treatment
Panel II (ATP II) guidelines were published, National Health and Nutrition
Examination Survey III data for 1988 to 1991 were used to estimate the num
ber of Americans requiring lipid-lowering therapy based on ATP II cut point
s. However, the guidelines recommend using clinical judgment to determine w
hether to initiate drug therapy in individuals whose low-density lipoprotei
n cholesterol levels remain above treatment goals with diet therapy but bel
ow the initiation level for drug therapy.
Methods: We analyzed updated (1988-1994) National Health and Nutrition Exam
ination Survey III data, based on a sample of 6796 adults aged 20 years and
older, to estimate the numbers of American adults with an elevated low-den
sity lipoprotein cholesterol level and requiring drug therapy using cut poi
nts vs clinical judgment as specified in ATP II guidelines.
Results: Assuming a 10% low-density lipoprotein cholesterol reduction with
diet, an estimated 10.4 million American adults require drug therapy based
on ATP II cut points. If we include individuals for whom the guidelines rec
ommend clinical judgment, the estimate increases to 28.4 million. The large
st increase occurs in individuals without known coronary heart disease but
with 2 or more risk factors: from 5.5 to 17.5 million. These high-risk indi
viduals have low-density lipoprotein cholesterol concentrations similar to
those in patients with coronary heart disease.
Conclusions: Since the ATP II guidelines were published, clinical judgment
has been informed by abundant clinical trial evidence establishing the safe
ty and benefit of lipid-lowering therapy. The large number of individuals a
t high risk for coronary heart disease emphasizes the need for cost-effecti
ve therapy to extend treatment to the greatest number of individuals who ma
y benefit.